Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sartorius AG's shares outstanding for the quarter that ended in Mar. 2026 was 69 Mil.
Sartorius AG's quarterly shares outstanding
stayed the same
from Dec. 2025 (69 Mil) to Mar. 2026 (69 Mil).
Sartorius AG's annual shares outstanding
increased
from Dec. 2024 (69 Mil) to Dec. 2025 (69 Mil).
It means Sartorius AGissued new shares from Dec. 2024 to Dec. 2025 .
Sartorius AG (OTCPK:SARTF) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Sartorius AG Shares Outstanding (EOP) Related Terms
Sartorius AG Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SARTF vs ISRG, BDX, MDLN: Shares Outstanding (EOP) Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Shares Outstanding (EOP) vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 69 Mil mean?
Sartorius AG (SARTF) has a Shares Outstanding (EOP) of 69 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Sartorius AG and its competitors.
Is Sartorius AG's Shares Outstanding (EOP) too high?
Sartorius AG's current Shares Outstanding (EOP) is 69 Mil. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Shares Outstanding (EOP) compare to ISRG and BDX?
Sartorius AG's Shares Outstanding (EOP) of 69 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Devices & Instruments company?
A good Shares Outstanding (EOP) depends on the Medical Devices & Instruments industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Sartorius AG and its competitors. Sartorius AG's current Shares Outstanding (EOP) is 69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $274.24, compared to a current price of $192.43 — trading 29.8% below its estimated fair value. The current Shares Outstanding (EOP) is 69 Mil. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Shares Outstanding (EOP) is 69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $192.43 is trading 29.8% below its estimated GF Value™ of $274.24.
GuruFocus considers Sartorius AG to be Significantly Undervalued.
Key valuation signals for SARTF:
Shares Outstanding (EOP): 69 Mil
GF Value™: $274.24 vs. price of $192.43 (29.8% below fair value)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
